Shanghai Haoyuan Chemexpress Co., Ltd.

Shanghai Stock Exchange 688131.SS

Shanghai Haoyuan Chemexpress Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2023: USD 70.72 M

Shanghai Haoyuan Chemexpress Co., Ltd. Total Non-Current Liabilities is USD 70.72 M for the year ending December 31, 2023, a 9.99% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Shanghai Haoyuan Chemexpress Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 64.30 M, a 80.48% change year over year.
Shanghai Haoyuan Chemexpress Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 35.63 M, a 578.51% change year over year.
Shanghai Haoyuan Chemexpress Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 5.25 M, a 90.51% change year over year.
Shanghai Haoyuan Chemexpress Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2019 was USD 2.76 M, a -2.95% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Shanghai Stock Exchange: 688131.SS

Shanghai Haoyuan Chemexpress Co., Ltd.

CEO	Mr. Baofu Zheng
IPO Date	June 8, 2021
Location	China
Headquarters	No. 3 Building, No. 1999
Employees	3,370
Sector	Health Care
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials

Description

Shanghai Haoyuan Chemexpress Co., Ltd. researches and develops pharmaceutical intermediates and small molecule drugs. It manufactures APIs and API intermediates, vitamin D series compounds, CRO building blocks, and CRO life bioscience compounds. The company was founded in 2006 and is headquartered in Shanghai, China.

Key trends

Past 5 years